NCT05969600

Brief Summary

Background: acute lymphoblastic leukemia is the most common childhood cancer and relapse is the main reason for treatment failure in childhood acute lymphoblastic leukemia. The aim of this study: is to assess the relapse of childhood acute lymphoblastic leukemia in pediatric patients treated in the Child's Central Teaching Hospital/ Baghdad. Methods: A retrospective study that reviewed 521 children with newly diagnosed ALL for children below 15 years during the period from 1st of January 2013 to 1st of March 2020 in the hemato-oncology ward in the Child's Central Teaching Hospital in Baghdad, with a total duration of follow-up for two years post last starting treatment (till 1st of March 2022 ).

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
521

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2013

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2013

Completed
7.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2020

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2022

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

June 8, 2023

Completed
2 months until next milestone

First Posted

Study publicly available on registry

August 1, 2023

Completed
Last Updated

August 1, 2023

Status Verified

July 1, 2023

Enrollment Period

7.2 years

First QC Date

June 8, 2023

Last Update Submit

July 23, 2023

Conditions

Leukemia, Acute

Outcome Measures

Primary Outcomes (1)

  • the relapse of childhood acute lymphoblastic leukemia in pediatric patients treated in the Child's Central Teaching Hospital/ Baghdad

    521 children reviewed with newly diagnosed ALL for children below 15 years

    the period from 1st of January 2013 to 1st of March 2020

Study Arms (2)

relapse group

non-relapse group

Eligibility Criteria

Age2 Months - 15 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

A retrospective study that reviewed 521 children with newly diagnosed ALL for children below 15 years during the period from 1st of January 2013 to 1st of March 2020 in the hemato-oncology ward in the Child's Central Teaching Hospital in Baghdad, with a total duration of follow-up for two years post last starting treatment (till 1st of March 2022 ).

You may qualify if:

  • patients diagnosed with acute lymphoplastic leukemia

You may not qualify if:

  • patients died before starting induction chemotherapy.
  • patients referred to another oncological center.
  • those who starting the treatment in another oncological center

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Leukemia

Condition Hierarchy (Ancestors)

Neoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
doctor

Study Record Dates

First Submitted

June 8, 2023

First Posted

August 1, 2023

Study Start

January 1, 2013

Primary Completion

March 1, 2020

Study Completion

March 1, 2022

Last Updated

August 1, 2023

Record last verified: 2023-07